Filing Details

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

(Amendment No. 7)*

 

Yield10 Bioscience, Inc.

(Name of Issuer)

 

Common Stock par value $0.01 per share

(Title of Class of Securities)

 

98585K862

(CUSIP Number)

 

Jack W. Schuler

100 N. Field Drive, Suite 360

Lake Forest, Illinois 60045

(224) 880-1210

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

February 3, 2021

(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

^* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

CUSIP No. 98585K862

 

1.		NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Jack W. Schuler
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ¨ (b)    x
3.		SEC USE ONLY
4.		SOURCE OF FUNDS (see instructions)   OO
5.		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨
6.		CITIZENSHIP OR PLACE OF ORGANIZATION   United States

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.		SOLE VOTING POWER   0
		8.		SHARED VOTING POWER   1,735,443 (1)
		9.		SOLE DISPOSITIVE POWER   0
		10.		SHARED DISPOSITIVE POWER   1,735,443 (1)

 

11.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,735,443 (1)
12.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    ¨
13.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 37.69% (2)
14.		TYPE OF REPORTING PERSON (see instructions) IN

 

(1) These numbers include the 840,429 shares of Common Stock underlying warrants exercisable at any time by the Jack W. Schuler Living Trust, the holder thereof.

 

(2) Based on information provided by the Issuer in a Form 8-K filed by the Issuer on February 2, 2021, this percentage is calculated assuming that the total outstanding number of shares of Common Stock was 4,604,632 on February 3, 2021 after taking into account the closing of the February 2021 Offering (as defined below).

 

 

CUSIP No. 98585K862

 

1.		NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Renate Schuler
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ¨ (b)    x
3.		SEC USE ONLY
4.		SOURCE OF FUNDS (see instructions)   OO
5.		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨
6.		CITIZENSHIP OR PLACE OF ORGANIZATION   United States

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.		SOLE VOTING POWER   21
		8.		SHARED VOTING POWER   33,998
		9.		SOLE DISPOSITIVE POWER   21
		10.		SHARED DISPOSITIVE POWER   33,998

 

11.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 34,019
12.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    ¨
13.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.74% (1)
14.		TYPE OF REPORTING PERSON (see instructions) IN

 

(1) Based on information provided by the Issuer in a Form 8-K filed by the Issuer on February 2, 2021, this percentage is calculated assuming that the total outstanding number of shares of Common Stock was 4,604,632 on February 3, 2021 after taking into account the closing of the February 2021 Offering (as defined below).

 

 

CUSIP No. 98585K862

 

1.		NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Schuler Family Foundation EIN – 36-4154510
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ¨ (b)    x
3.		SEC USE ONLY
4.		SOURCE OF FUNDS (see instructions)   PF
5.		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨
6.		CITIZENSHIP OR PLACE OF ORGANIZATION   United States

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.		SOLE VOTING POWER   33,998
		8.		SHARED VOTING POWER   0
		9.		SOLE DISPOSITIVE POWER   33,998
		10.		SHARED DISPOSITIVE POWER

 

11.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 33,998
12.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    ¨
13.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.74% (1)
14.		TYPE OF REPORTING PERSON (see instructions) CO

 

(1) Based on information provided by the Issuer in a Form 8-K filed by the Issuer on February 2, 2021, this percentage is calculated assuming that the total outstanding number of shares of Common Stock was 4,604,632 on February 3, 2021 after taking into account the closing of the February 2021 Offering (as defined below).

 

 

CUSIP No. 98585K862

 

1.		NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Jack W. Schuler Living Trust
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ¨ (b)    x
3.		SEC USE ONLY
4.		SOURCE OF FUNDS (see instructions)   PF
5.		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨
6.		CITIZENSHIP OR PLACE OF ORGANIZATION   United States

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.		SOLE VOTING POWER   1,701,445 (1)
		8.		SHARED VOTING POWER   0
		9.		SOLE DISPOSITIVE POWER   1,701,445 (1)
		10.		SHARED DISPOSITIVE POWER

 

11.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,701,445 (1)
12.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    ¨
13.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 36.95% (2)
14.		TYPE OF REPORTING PERSON (see instructions)   OO

 

(1) These numbers include the 840,429 shares of Common Stock underlying warrants exercisable at any time by the Jack W. Schuler Living Trust, the holder thereof.

 

(2) Based on information provided by the Issuer in a Form 8-K filed by the Issuer on February 2, 2021, this percentage is calculated assuming that the total outstanding number of shares of Common Stock was 4,604,632 on February 3, 2021 after taking into account the closing of the February 2021 Offering (as defined below).

 

 

CUSIP No. 98585K862 

 

Explanatory Note

 

This Amendment No. 7 (this “Amendment No. 7”) amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission (the “Commission”) on August 29, 2014, by the reporting persons identified therein, as amended by Amendment No. 1 filed with the Commission on June 23, 2015, as further amended by Amendment No. 2 filed with the Commission on August 2, 2017, as further amended by Amendment No. 3 filed with the Commission on June 26, 2019, as further amended by Amendment No. 4 filed with the Commission on February 6, 2020, as further amended by Amendment No. 5 filed with the Commission on February 13, 2020, and as further amended by Amendment No. 6 filed with the Commission on August 31, 2020 by the Reporting Persons identified therein (as cumulatively amended, the “Schedule 13D”), with respect to shares of common stock, par value $0.01 per share of Yield10 Bioscience, Inc. (formerly Metabolix, Inc.), a Delaware corporation (the “Issuer”) beneficially owned by the Reporting Persons. Except as amended or supplemented in this Amendment No. 7, all other information in the Schedule 13D is as set forth previously. Capitalized terms used in this Amendment No. 7 but not defined herein shall have the meanings previously ascribed thereto in the Schedule 13D.

 

Item 1.  Security and Issuer.

 

This statement on Schedule 13D relates to the common stock, $0.01 par value per share, of Yield10 Bioscience, Inc., a Delaware corporation (“Common Stock”). The principal executive office of the Issuer is 19 Presidential Way, Woburn, MA 01801.

 

Item 4.  Purpose of Transaction.

 

On January 31, 2021, the Issuer entered into an Underwriting Agreement (the “Underwriting Agreement”) with Maxim Group LLC (the “Underwriter”), pursuant to which the Issuer sold, in an underwritten public offering by the Issuer (the “February 2021 Offering”), 1,040,000 shares of the Issuer’s Common Stock at a public offering price of $12.25 per share.

 

The shares of Common Stock were offered by the Issuer pursuant to a registration statement on Form S-3 (File No. 333-237539), as initially filed with the Securities and Exchange Commission (the “Commission”) on April 1, 2020, and declared effective by the Commission on April 10, 2020, and a prospectus supplement dated February 2, 2021. The February 2021 Offering closed on February 3, 2021.

 

On February 3, 2021, the Jack W. Schuler Living Trust acquired 101,400 shares of Common Stock of the Issuer in the February 2021 Offering.

 

Information regarding the purchases described above in this Item 4 is set forth in Item 5(c).

 

The Reporting Persons reserve the right to formulate plans and/or make proposals, and take such actions with respect to their investment in the Issuer, including, subject to applicable law, (i) to hold their Common Stock as a passive investor or as an active investor, (ii) to acquire beneficial ownership of additional Common Stock in the open market, in privately negotiated transactions or otherwise, (iii) to dispose of all or part of their holdings of Common Stock, (iv) to take other actions which could involve one or more of the types of transactions or have one or more of the results described in Item 4 of Schedule 13D, or (v) to change their intention with respect to any or all of the matters referred to in Item 4 of Schedule 13D.

 

Item 5.  Interest in Securities of the Issuer.

 

(a)

 

The 1,735,464 shares of Common Stock for which this schedule is filed consist of (i) 21 shares owned by Renate Schuler, representing less than 0.1% of the shares of the Common Stock of the Issuer outstanding, (ii) 1,701,445 shares owned by the Jack W. Schuler Living Trust (including 840,429 shares of Common Stock underlying warrants), representing approximately 36.95% of the shares of the Common Stock of the Issuer outstanding, and (iii) 33,998 shares owned by the Schuler Family Foundation, representing approximately 1.06% of the shares of the Common Stock of the Issuer outstanding. The foregoing percentages assume that, based on information provided by the Issuer on February 2, 2021, the total outstanding number of shares of Common Stock of the Issuer was 4,604,632 on February 3, 2021, after taking into account the closing of the February 2021 Offering (as defined above).

 

 

CUSIP No. 98585K862

 

Mr. Schuler disclaims beneficial ownership in (i) the 21 shares owned by his wife, Renate Schuler and (ii) the 33,998 shares owned by the Schuler Family Foundation, a tax-exempt private operating foundation of which Mr. Schuler and Ms. Schuler are two of the three directors. Ms. Schuler disclaims beneficial ownership in the 33,998 shares owned by the Schuler Family Foundation.

 

(b)

 

Jack W. Schuler:

 

(i)

Sole power to vote or to direct the vote: 0

(ii)

Shared power to vote or direct the vote: 1,735,443

(iii)

Sole power to dispose or to direct the disposition of: 0

(iv)

Shared power to dispose of to direct the disposition of: 1,735,443

  

Renate Schuler:

 

(i)

Sole power to vote or to direct the vote: 21

(ii)

Shared power to vote or direct the vote: 33,998

(iii)

Sole power to dispose or to direct the disposition of: 21

(iv)

Shared power to dispose of to direct the disposition of: 33,998

 

The Schuler Family Foundation:

 

(i)

Sole power to vote or to direct the vote: 33,998

(ii)

Shared power to vote or direct the vote: 0

(iii)

Sole power to dispose or to direct the disposition of: 33,998

(iv)

Shared power to dispose of to direct the disposition of: 0

 

Jack W. Schuler Living Trust:

 

(i)

Sole power to vote or to direct the vote: 1,701,445

(ii)

Shared power to vote or direct the vote: 0

(iii)

Sole power to dispose or to direct the disposition of: 1,701,445

(iv)

Shared power to dispose of to direct the disposition of: 0

 

(c)

 

Except as set forth in Schedule 1, the Reporting Persons have not effected any transaction in the shares of Common Stock since their most recent Schedule 13D filing.

 

(d)

 

Except as set forth in this Amendment No. 7, to the knowledge of the Reporting Persons, no person had the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, securities covered by this Schedule 13D.

 

(e) Not Applicable.

 

Item 6. Contracts, Arrangements, Understandings or Relationships with respect to Securities of the Issuer.

 

Except as otherwise set forth in this Schedule 13D and the exhibits hereto, there are no contracts, arrangements, understandings or relationships between the persons named in Item 2 and any other person with respect to any securities of the Issuer.

 

 

CUSIP No. 98585K862

 

Item 7. Material to be filed as Exhibits.

 

Exhibit	Title
1	Amended and Restated Joint Filing Agreement, dated as of August 1, 2017, by and among Jack W. Schuler, Renate Schuler, the Schuler Family Foundation and Jack W. Schuler Living Trust (incorporated by reference to the Amendment No. 2 to Schedule 13D filed by the Reporting Persons on August 2, 2017).
2	Underwriting Agreement, dated as of January 31, 2021, by and between Yield10 Bioscience, Inc. and Maxim Group LLC as representative of the several underwriters, if any, named on Schedule I thereto (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed by the Issuer with the Commission on February 2, 2021).

 

 

CUSIP No. 98585K862

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 4, 2021	/s/ Jack W. Schuler
	Jack W. Schuler
Dated: February 4, 2021	/s/ Renate Schuler
	Renate Schuler
	SCHULER FAMILY FOUNDATION
Dated: February 4, 2021	/s/ Jack W. Schuler
	Name: Jack W. Schuler
	Title: Director
	JACK W. SCHULER LIVING TRUST
Dated: February 4, 2021	/s/ Jack W. Schuler
	Name: Jack W. Schuler
	Title: Trustee

 

 

CUSIP No. 98585K862

 

SCHEDULE 1

 

Shares Acquired or Sold by the Reporting Persons Since Their Most Recent Schedule 13D Filing:

 

1.	JACK W. SCHULER LIVING TRUST

 

Trade Date	Nature of Transaction (Purchase/Sale)	Number of Shares	Price Per Share (1)
02/03/2021	Purchase	101,400	$12.25

 

(1)	Inclusive of brokerage fees.